Align Technology reports Q1 2026 results tonight — and the setup heading into the print is more nuanced than the week's price action suggests.
The stock fell 4% on Tuesday to $177.28, extending a 9.2% weekly decline after what had been a solid April recovery. The dip looks sharp on the surface, but the short-side data tells a more cautious positioning story — one where bears have actually been trimming, not pressing.
Short sellers have been reducing exposure for the past week. SI % of free float eased to roughly 6.0% on April 28, down from a peak near 6.6% in mid-April. That's still a meaningful step up from the 4.3% level recorded in early April — shorts accumulated quickly in the first half of the month — but the direction since mid-April has been one of modest unwinding. Borrowing conditions remain exceptionally easy: cost to borrow is just 0.37%, down around 12% over the past week, and availability in the lending pool is wide, with no squeeze pressure in sight. The ORTEX short score of 41.7 sits in the lower half of the universe — not a setup that flags aggressive short-side conviction going into earnings.
Options positioning offers a mild defensive lean, but not an alarming one. The put/call ratio of 1.26 is running slightly above its 20-day average of 1.24 — a z-score of just 0.34 — well within normal range. For context, the 52-week PCR high is 2.23 and the low is 0.76, so the current level is closer to the middle of that range. What is notable is the structural drift: the PCR has climbed from around 1.10 in late March to where it is now, suggesting options traders have gradually added a hedge as the stock ran up and earnings approached. The tilt is cautious, not panicked.
The Street has been broadly constructive in recent weeks. Morgan Stanley raised its target to $188 on April 24 while holding its Equal-Weight rating — cautious on valuation even after lifting expectations. Piper Sandler is more bullish, nudging its Overweight target up to $235 on April 21. Citigroup initiated with a Buy and a $240 target on April 15, the most aggressive fresh call. Barclays upgraded to Overweight in mid-March, adding to the positive tilt. The consensus mean target of around $207 implies roughly 17% upside from Tuesday's close, and the forward EPS growth picture scores in the 99th percentile of the universe — a factor that bulls lean on heavily. Bears focus on declining average selling prices and the fragility of the US consumer orthodontic market, where a return to growth remains uncertain. Valuation is undemanding on some measures — an EV/EBITDA near 10x and a P/E around 15x — though both metrics have eased as the stock sold off this week.
The Q4 2025 print in early February offered a useful template. ALGN beat expectations convincingly that quarter — revenue of $1.05 billion versus $995 million a year earlier — and the stock jumped nearly 12% the next day, adding another 14% over the following week. Capital Research added 1.8 million shares in Q1, making it the second-largest institutional holder, while Fidelity built a position of over 1.1 million shares — both moves reflecting confidence after that February beat.
Close peer Envista slid 2.6% this week and DENTSPLY Sirona fell 4.3%, suggesting the broader dental and health-care equipment space was under pressure well before ALGN's own drop. That sector softness adds context to Tuesday's decline but also means the bar for a positive read-through from tonight's print may be slightly lower.
The key question from tonight is whether the US market is showing any signs of life, or whether ALGN's international momentum remains the primary engine — the answer will set the tone for how the Street frames its 2026 guidance narrative.
See the live data behind this article on ORTEX.
Open ALGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
